Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone

Xenobiotica

Volumn 39, Issue 1, 2009, Pages 1-10

  Yoo, H H ^a   Kim, N S ^b   Lee, J ^a   Sohn, D R ^c   Jin, C ^a   Kim, D H ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c Soonchunhyang University   (South Korea)

Author keywords

Cytochrome P450s (CYPs); Eperisone; Human intestinal microsome; Human liver microsome; In vitro metabolism

Indexed keywords

ASTEMIZOLE; CYTOCHROME P450; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; DRUG METABOLITE; EBASTINE; EPERISONE; FURAFYLLINE; ISOENZYME; KETOCONAZOLE; QUINIDINE; RECOMBINANT ENZYME; SULFAPHENAZOLE;

ARTICLE; BIOTRANSFORMATION; CARBONYLATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME METABOLISM; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; INTESTINE CELL; KINETICS; LIVER MICROSOME; MICROSOME; OXIDATION REDUCTION REACTION; STEREOCHEMISTRY;

ANTIBODIES; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INTESTINES; ISOENZYMES; KINETICS; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; MUSCLE RELAXANTS, CENTRAL; OXIDATION-REDUCTION; PROPIOPHENONES; RECOMBINANT PROTEINS;

EID: 61649116922     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802509448     Document Type: Article

References (12)

1. Boulton DW, Fawcett JP. (2001). The pharmacokinetics of levosalbutamol: what are the clinical implications? Clinical Pharmacokinetics 40:23-40.
2. Fujita T, Takamatsu T, Hisamoto T, Tsutsumi J, Kinoshita K, Kanai T. (1981). Studies on the metabolic fate of 4′-ethyl-2-methyl-3- piperidinopropiophenone hydrochloride (1): absorption, distribution and excretion in rats and guinea pigs. Pharmacometrics 21:835-846.
3. Hasegawa Y, Kaku S, Araki H, Otomo S. (1992). Sigma receptor modulation of the muscle relaxant action of eperisone. European Neuropsychopharmacology 2:157-159.
4. Kaminsky LS, Zhang QY. (2003). The small intestine as a xenobiotic-metabolizing organ. Drug Metabolism and Disposition 31:1520-1525.
5. Lu H. (2007). Stereoselectivity in drug metabolism. Expert Opinions on Drug Metabolism and Toxicology 3:149-158.
6. Matsunaga M, Uemura Y, Yonemoto Y, Kanai K, Etoh H, Tanaka S, Atsuta Y, Nishizawa Y, Yamanishi Y. (1997). Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Japanese Journal of Pharmacology 73:215-220.
7. Mihara K, Matsumura M, Yoshioka E, Hanada K, Nakasa H, Ohmori S, Kitada M, Ogata H. 2001. Intestinal first-pass metabolism of eperisone in the rat. Pharmaceutical Research 18:1131-1137.
8. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. (2006). The human intestinal cytochrome P450 'PIE'. Drug Metabolism and Disposition 34:880-886.
9. Takamatsu F, Yamazaki K, Kayano M. (1992). Determination of eperisone in human plasma by gas chromatography-mass spectrometry. Journal of Chromatography A 584:261-266.
10. Takamatsu T, Horie T, Tsutsumi J, Kanai T. (1993). The metabolism of eperisone hydrochloride in laboratory animals and man. Iyakuhin Kenkyu 24:520-532. [in Japanese]
11. Tanaka K, Kaneko T, Yamatsu K. (1981). Effects of 4′-ethyl-2- methyl-3-piperidinopropiophenone on experimental rigidity and spinal cord activities. Folia Pharmacologica Japonica 77:511-520.
12. Zsila F, Hollosi M, Gergely A. (2000). Stereochemical study of tolperidone, a muscle relaxant agent, by circular dichroism and ultraviolet spectroscopy. Chirality 12:720-726.